CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Epinephrine Bitartrate, Lidocaine Hydrochloride Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2012-02-22. Latest FDA row update: 2026-09-22.
FDA lists 22 package records, with companies: Fresenius Kabi USA, LLC, Hospira, Inc., a Pfizer Company. Package NDCs: 0409-1209-01, 0409-3177-01, 0409-3178-01, 0409-3178-02, 0409-3178-03, 0409-3181-01, 0409-3182-01, 0409-3182-02, 0409-3182-03, 0409-3183-01, 63323-481-57, 63323-482-17, 63323-482-27, 63323-482-57, 63323-483-27, 63323-483-57, 63323-487-17, 63323-487-37, 63323-488-17, 63323-488-37, 63323-489-17, 63323-489-27.
FDA shortage reason: Demand increase for the drug; Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Fresenius Kabi USA, LLC | 63323-487-17 | Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-487-37 | Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-488-17 | Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17) | Unavailable | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-488-37 | Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-489-17 | Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-489-27 | Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27) | Unavailable | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-481-57 | Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57) | Unavailable | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-482-17 | Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-482-27 | Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-482-57 | Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57) | Unavailable | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-483-27 | Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-483-57 | Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57) | Available | 2026-09-15 |
| Hospira, Inc., a Pfizer Company | 0409-3182-03 | Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03) | Limited Availability | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-3178-01 | Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-3177-01 | Lidocaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-3178-02 | Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-3182-01 | Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-3183-01 | Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-3181-01 | Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-3178-03 | Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03) | Limited Availability | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-1209-01 | Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-3182-02 | Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02) | Limited Availability | 2026-09-22 |
Source facts
Grouped generic ingredient: Epinephrine Bitartrate, Lidocaine Hydrochloride Injection · 22 package records
Therapeutic categories: Anesthesia, Pediatric
Dosage forms: Injection
Routes: EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.